Chronic Kidney Disease | Current Treatment | US | 2016
The United States has seen a dramatic rise in the prevalence of chronic kidney disease (CKD) and its sequelae—namely, diabetes and hypertension. Patients with CKD are typically co-managed by many different physician types, including nephrologists, endocrinologists, and primary care physicians (PCPs). Understanding referrals patterns between these physicians for both early- and late-stage CKD patients generates greater insight into patient management, including treatment and prescribing practices. This content stream explores how early- and late-stage CKD-ND patients are referred, co-managed, diagnosed, and treated.
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
